-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

Scott Adams previously asked President Donald Trump to intervene with his insurer over delayed cancer treatment ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...